BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18

• Press Releases

  OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases

  December 11, 2025

   · 

  4 min read
• Press Releases

  Immunovant Announces Pricing of $550 Million Common Stock Financing

  December 11, 2025

   · 

  4 min read
• Press Releases

  The European Patent Office Intends to Grant a New Patent for IRLAB’s Mesdopetam

  December 11, 2025

   · 

  2 min read
• Press Releases

  Genmab to Hold 2025 R&D Update and ASH Data Review Meeting

  December 11, 2025

   · 

  3 min read
• Press Releases

  Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial

  December 11, 2025

   · 

  11 min read
• Press Releases

  Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

  December 11, 2025

   · 

  7 min read
• Press Releases

  BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025

  December 11, 2025

   · 

  5 min read
• Press Releases

  Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

  December 11, 2025

   · 

  9 min read
• Press Releases

  Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis

  December 11, 2025

   · 

  7 min read
• Press Releases

  Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS

  December 11, 2025

   · 

  6 min read